A PHASE I, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF SATRALIZUMAB IN ADULT PATIENTS WITH AQP4 ANTIBODY-POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER WITH BODYWEIGHT >100 KG

14208ROCHE-WP44131OpenA PHASE I, MULTICENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF SATRALIZUMAB IN ADULT PATIENTS WITH AQP4 ANTIBODY-POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER WITH BODYWEIGHT >100 KG WP44131NCT99999999IndustrialAdultTreatmentOtherOsborne, BenjaminGeorgetown University Medical Center : David Pisfil; Lombardi Comprehensive Cancer Center : David PisfilGUMC Neurology; GUMC PFS10694David PisfilDavid Pisfilddp39@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>